Resverlogix Corp News - RVX

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF...

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”...

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Announces Appointment of New Chief Scientific Officer

CALGARY, Alberta, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation...

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

CALGARY, Alberta, May 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix", or "the Company...

Resverlogix Announces One-Year Extension of Debenture

CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”...

Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Corp. to Webcast Live at VirtualInvestorConferences.com March 10th

CALGARY, Alberta, March 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX), a global...

Life Sciences Virtual Investor Conference: Company Executives Present Live March 10th

NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada

CALGARY, Alberta, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment

CALGARY, Alberta, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to...

Resverlogix Announces Corporate Update Webcast and Conference Call

CALGARY, Alberta, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment

CALGARY, Alberta, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”...

alvaroc2 8 years ago

TA breaking 2,50 try 3 $.

👍️0

alvaroc2 8 years ago

No analist cover at the moment, when news came.....

👍️0

alvaroc2 8 years ago

Good evening clase 2,41 near high 2,47,good news and many conferences in march and april.

👍️0

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Resverlogix Corp (RVX)

Empower your portfolio: Real-time discussions and actionable trading ideas.

RVX News

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

Resverlogix Announces Appointment of New Chief Scientific Officer

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

Resverlogix Announces One-Year Extension of Debenture

Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

Resverlogix Corp. to Webcast Live at VirtualInvestorConferences.com March 10th

Life Sciences Virtual Investor Conference: Company Executives Present Live March 10th

Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada

Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment

Resverlogix Announces Corporate Update Webcast and Conference Call

Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment

RVX Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Resverlogix Corp (RVX) News

Resverlogix Corp (RVX)

Empower your portfolio: Real-time discussions and actionable trading ideas.

RVX News

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

Resverlogix Announces Appointment of New Chief Scientific Officer

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

Resverlogix Announces One-Year Extension of Debenture

Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

Resverlogix Corp. to Webcast Live at VirtualInvestorConferences.com March 10th

Life Sciences Virtual Investor Conference: Company Executives Present Live March 10th

Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada

Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment

Resverlogix Announces Corporate Update Webcast and Conference Call

Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment

RVX Discussion

Your Recent History

Go Ad-Free